Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × ALK-positive NSCLC × Clear all

Phase

Status

Unknown 3 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1792 Neoplasms 1514 Carcinoma, Non-Small-Cell Lung 1044 Prostatic Neoplasms 954 Colorectal Neoplasms 883 Lung Neoplasms 812 Pancreatic Neoplasms 578 Carcinoma, Hepatocellular 543 Leukemia, Myeloid, Acute 533 Stomach Neoplasms 510 Ovarian Neoplasms 506 Neoplasm Metastasis 490 Multiple Myeloma 482 Recurrence 410 Melanoma 387 Uterine Cervical Neoplasms 371 Squamous Cell Carcinoma of Head and Neck 363 Head and Neck Neoplasms 356 Brain Neoplasms 352 Esophageal Neoplasms 323 Precursor Cell Lymphoblastic Leukemia-Lymphoma 315 Lymphoma 311 Endometrial Neoplasms 308 Triple Negative Breast Neoplasms 294 Glioblastoma 288 Rectal Neoplasms 283 Sarcoma 269 Urinary Bladder Neoplasms 268 Hematologic Neoplasms 262 Colonic Neoplasms 260

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07491497 2026-04-14

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

TRIANA Biomedicines, Inc.

Phase 1/2 Recruiting

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡